The latest biotech news

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

Did Bavarian Nordic cheat on its clinical results?

The hedge fund Kerrisdale Capital just published a report explaining its position in Bavarian Nordic, showing that the Danish company’s lead candidate has ineffective results. Kerrisdale is inviting other investors to leave their shares in the company before it’s too late. Bavarian Nordic is under attack! Kerrisdale Capital, an hedge fund with track records in […]

August 5, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

Interview with Fabrice Plasson, Amoéba’s CEO: “We created a biocide using microorganisms”

Water treatment against pathogens has not changed since 1914 when we first discovered the use of chlorine. Industrial manufacturers are still using such chemicals to decontaminate waters involved in their process but can only destroy 0,5% of pathogens! The French company Amoéba, has discovered a way to eliminate 100% of pathogens without using any chemicals! […]

August 5, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 4 Aug 2015

A 100% Successful Ebola Vaccine Available in a Record Time

It’s a really good news in the fight against Ebola. A vaccine has shown 100% success to prevent the disease during the outbreak in Guinea! The vaccine, which has been tested in a record time, can be the key to end the west African epidemics. In an interim analysis published by The Lancet, the new vaccine has […]

August 4, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 Aug 2015

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company’s last results. The successor of Chris Viehbacher took the opportunity to show the good results made by its Biotech pipeline. Genzyme, the rare diseases arm of Sanofi, was an important growth driver again this quarter. Total sales of the Rare […]

August 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 Aug 2015

€41M for a Rising Star of Synthetic Biology: Ginkgo Bioworks

Once will not hurt, we’ll speak a bit about an inspiring US-based company. A synthetic biology start-up from the worlds biggest biocluster is on its road to success. Shortly after its Series A, Boston-based Ginkgo Bioworks goes on better and raises $45M (€41M). The microbe engineer makes food taste moreish and perfume smell better. And […]

August 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Aug 2015

Green light for Ascendis’ Phase III in Growth Hormone Deficiency

It seems like the €48M Series D financing and the public introduction on the NASDAQ have paid off. Danish Ascendis Pharma announced positive top-line results from a Phase II study that evaluated the once-weekly TransCon Growth Hormone in children with growth hormone deficiency. After Zosano, Ascendis was the second European company that went public at […]

August 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Jul 2015

UCB’s Lupus treatment breaks down in Phase III

Big disappointment for Belgian UCB. After 9 years of research, its lead candidate in Immunology, designed to treat Systemic Lupus Erythematosus, failed in Phase III. The drug was acquired from Immunomedics in 2006 and costed at least $38M. Epratuzumab is a monoclonal antibody for the treatment of Systemic Lupus Erythematosus, developed by Immunomedics. For the […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Jul 2015

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Just as Boehringer Ingelheim, Bayer HealthCare expands its cancer portfolio this week. The German company is inclined to shell out €190M for a drug that interacts with the peculiar metabolism of cancer cells. Its developer, Sprint Bioscience AB, is a Swedish company founded in 2009, from former members of AstraZeneca, Biovitrum, and Pharmacia. Sprint Bioscience is a […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Jul 2015

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Boehringer Ingelheim puts a new pillar in its oncology pipeline. The German giant acquired a Phase II compound for the treatment of lung cancer from the Korean pharma company Hamni. Non-small cell lung cancer makes up about 90% of all lung cancers. A targeted therapy includes the inhibition of the epidermal growth factor receptor (EGFR), […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 29 Jul 2015

How to create a late-stage Biotech company in record time? Ask Novartis!

Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has already three candidates in phase II and just raised $119m (approximately €108m) from private investors! Mereo has everything […]

July 29, 2015 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

AstraZeneca Adds New Antisense Drugs to its Pipeline

Did Bavarian Nordic cheat on its clinical results?

Interview with Fabrice Plasson, Amoéba’s CEO: “We created a biocide using microorganisms”

A 100% Successful Ebola Vaccine Available in a Record Time

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

€41M for a Rising Star of Synthetic Biology: Ginkgo Bioworks

Green light for Ascendis’ Phase III in Growth Hormone Deficiency

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

UCB’s Lupus treatment breaks down in Phase III

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

How to create a late-stage Biotech company in record time? Ask Novartis!

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!